Predicting subsite interactions of plasmin with substrates and inhibitors through computational docking analysis

Plasmin plays important roles in various physiological systems. The identification of inhibitors controlling its regulation represents a promising drug-discovery challenge. To develop selective inhibitors of plasmin, structural information of the binding modes is crucial. Here, a computational docking study was conducted to provide structural insight into plasmin subsite interactions with substrates/inhibitors. Predicted binding modes of two peptide-substrates (D/L-Ile-Phe-Lys), and potent and weak inhibitors (YO-2 and PKSI-527) suggested non-prime and prime subsite interactions relevant to recognition by plasmin. Predicted binding modes also correlated well with the experimental structure–activity relationships for plasmin substrates/inhibitors, namely the differences of KM values between the D- and L-peptide-substrates and inhibitory potencies of YO-2 and PKSI-527. In particular, interaction observed at a hydrophobic pocket near S2 and at a tunnel-shaped hydrophobic S1′ was strongly suggested to be significantly involved in tight binding of inhibitors to plasmin. Our present findings may aid in the design of potent and selective plasmin inhibitors.

[1]  Jean M. Severin,et al.  Identification of novel inhibitors of urokinase via NMR-based screening. , 2000, Journal of medicinal chemistry.

[2]  Y. Tsuda,et al.  Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikrein. , 1989, Chemical & pharmaceutical bulletin.

[3]  R. Huber,et al.  The ternary microplasmin–staphylokinase–microplasmin complex is a proteinase–cofactor–substrate complex in action , 1998, Nature Structural Biology.

[4]  Y. Okada,et al.  Enzyme-Controlling Medicines: Introduction , 1997, Seminars in thrombosis and hemostasis.

[5]  C. Seto,et al.  Structure-activity studies of cyclic ketone inhibitors of the serine protease plasmin: design, synthesis, and biological activity. , 2006, Bioorganic & medicinal chemistry.

[6]  Y. Tsuda,et al.  Synthesis of plasmin substrates and relationship between their structure and plasmin activity. , 2009, International journal of peptide and protein research.

[7]  Y. Tsuda,et al.  Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors. , 2001, Chemical & pharmaceutical bulletin.

[8]  Y. Tsuda,et al.  Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship. , 2000, Chemical & pharmaceutical bulletin.

[9]  J. Tang,et al.  Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. , 1998, Science.

[10]  H. Yamada,et al.  Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. , 2007, Current pharmaceutical design.

[11]  Jonas Boström,et al.  Assessing the performance of OMEGA with respect to retrieving bioactive conformations. , 2003, Journal of molecular graphics & modelling.

[12]  J. A. Grant,et al.  Gaussian docking functions. , 2003, Biopolymers.

[13]  Y. Okada,et al.  Development of active center-directed plasmin and plasma kallikrein inhibitors and studies on the structure-inhibitory activity relationship. , 1993, Chemical & pharmaceutical bulletin.

[14]  K. Robbins,et al.  The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. , 1967, The Journal of biological chemistry.

[15]  A. Hillisch,et al.  Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban). , 2010, Current topics in medicinal chemistry.

[16]  M. Judex,et al.  Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more. , 2005, The American journal of pathology.

[17]  Yang Liu,et al.  Structure-guided design of peptide-based tryptase inhibitors. , 2006, Biochemistry.

[18]  Jean M. Severin,et al.  Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. , 2000, Structure.

[19]  E. Davie,et al.  Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. , 1990, The Journal of biological chemistry.

[20]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[21]  J. Andrew Grant,et al.  A smooth permittivity function for Poisson–Boltzmann solvation methods , 2001, J. Comput. Chem..